JP6105479B2 - 血清アルブミンに結合する設計リピートタンパク質 - Google Patents

血清アルブミンに結合する設計リピートタンパク質 Download PDF

Info

Publication number
JP6105479B2
JP6105479B2 JP2013540386A JP2013540386A JP6105479B2 JP 6105479 B2 JP6105479 B2 JP 6105479B2 JP 2013540386 A JP2013540386 A JP 2013540386A JP 2013540386 A JP2013540386 A JP 2013540386A JP 6105479 B2 JP6105479 B2 JP 6105479B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
ankyrin repeat
binding protein
repeat domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013540386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501509A (ja
Inventor
シュタイナー，ダニエル
ビンツ，ハンス・カスパル
グロッティ−ゲオルギエヴァ，マヤ
メルツ，フリーダー・ヴェー
フィリップス，ダグラス
ゾンダーエッガー，イフォ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of JP2014501509A publication Critical patent/JP2014501509A/ja
Application granted granted Critical
Publication of JP6105479B2 publication Critical patent/JP6105479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013540386A 2010-11-26 2011-11-25 血清アルブミンに結合する設計リピートタンパク質 Active JP6105479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10192711 2010-11-26
EP10192711.9 2010-11-26
PCT/EP2011/071083 WO2012069654A1 (en) 2010-11-26 2011-11-25 Designed repeat proteins binding to serum albumin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016211658A Division JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Publications (2)

Publication Number Publication Date
JP2014501509A JP2014501509A (ja) 2014-01-23
JP6105479B2 true JP6105479B2 (ja) 2017-03-29

Family

ID=43858162

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013540386A Active JP6105479B2 (ja) 2010-11-26 2011-11-25 血清アルブミンに結合する設計リピートタンパク質
JP2013540387A Active JP6173216B2 (ja) 2010-11-26 2011-11-25 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
JP2016211658A Pending JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013540387A Active JP6173216B2 (ja) 2010-11-26 2011-11-25 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
JP2016211658A Pending JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Country Status (13)

Country Link
US (5) US9284361B2 (enExample)
EP (3) EP2643348B1 (enExample)
JP (3) JP6105479B2 (enExample)
KR (3) KR101782790B1 (enExample)
CN (3) CN113278077A (enExample)
AU (2) AU2011333665B2 (enExample)
BR (3) BR112013012786B1 (enExample)
CA (2) CA2818969C (enExample)
DK (1) DK2643349T3 (enExample)
ES (2) ES2981441T3 (enExample)
PL (1) PL2643349T3 (enExample)
RU (2) RU2636552C2 (enExample)
WO (2) WO2012069655A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048216A (ja) * 2010-11-26 2017-03-09 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血清アルブミンに結合する設計リピートタンパク質

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
BR112014032316A2 (pt) * 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
US10093740B2 (en) * 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105143270B (zh) * 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
US10665324B2 (en) 2014-07-07 2020-05-26 Yeda Research And Development Co. Ltd. Method of computational protein design
EP3277711B9 (en) 2015-04-02 2023-08-16 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin
AU2017331329B2 (en) 2016-09-22 2020-10-29 Molecular Partners Ag Recombinant binding proteins and their use
DK3535397T3 (da) * 2016-11-01 2022-01-31 Arrowhead Pharmaceuticals Inc Alfa-v-beta-6-integrin-ligander og anvendelser deraf
WO2018165046A1 (en) 2017-03-07 2018-09-13 Igc Bio, Inc. A computational pipeline for antibody modeling and design
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
US12448458B2 (en) 2018-06-15 2025-10-21 Universität Bern Ligands to light or its receptor LTßR for use in haematologic malignancies
EP3864054A1 (en) 2018-10-08 2021-08-18 Universität Zürich Her2-binding tetrameric polypeptides
EP3883919A1 (en) 2018-11-21 2021-09-29 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
US20220088144A1 (en) 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
JP2022521428A (ja) 2019-02-25 2022-04-07 ザ・ユニバーシティ・オブ・シカゴ 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
WO2020207771A1 (en) 2019-04-10 2020-10-15 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
CA3139164A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
WO2020245171A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
SG11202112921VA (en) 2019-06-04 2021-12-30 Molecular Partners Ag Multispecific proteins
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
CA3161321A1 (en) 2019-12-11 2021-06-17 Victor LEVITSKY Recombinant peptide-mhc complex binding proteins and their generation and use
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
US20230151118A1 (en) 2020-04-06 2023-05-18 Universität Zürich Artc1 ligands for cancer treatment
WO2021224686A1 (en) 2020-05-06 2021-11-11 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
CA3178785A1 (en) 2020-05-14 2021-11-18 Nicolo RIGAMONTI Multispecific proteins
JP2023528207A (ja) * 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｃｄ４０結合タンパク質及びそれらの使用
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
US11981710B2 (en) * 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2022038193A1 (en) 2020-08-18 2022-02-24 Universität Zürich A cd25-biased anti-il-2 antibody
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
EP4263608A1 (en) 2020-12-16 2023-10-25 Molecular Partners AG Recombinant cd3 binding proteins and their use
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
EP4291901B1 (en) 2021-02-11 2025-05-07 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
EP4043481A1 (en) * 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2022190010A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd33 engagers
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
EP4323388B1 (en) 2021-04-16 2025-01-29 Athebio AG N-terminal capping modules of ankyrin repeat domains
MX2024001691A (es) 2021-08-05 2024-04-19 Immunos Therapeutics Ag Medicamentos de combinación que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).
IL310612A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag HLA-B57 is different with increased expression levels
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
KR20240122764A (ko) 2021-12-14 2024-08-13 몰리큘라 파트너스 아게 이중 결합 특이성을 갖는 설계된 반복 도메인과 이의 용도
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
CN119731200A (zh) 2022-08-01 2025-03-28 分子合作伙伴股份公司 经电荷修饰设计的重复结构域及其用途
WO2023194628A2 (en) 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
WO2024133013A1 (en) 2022-12-19 2024-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Means and methods to target endogenous condensates
CN121002056A (zh) 2023-02-08 2025-11-21 免疫标记治疗股份公司 β2微球蛋白、HLA重链多肽、和CD47–SIRPα抑制剂的融合蛋白
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
AU2024286934A1 (en) 2023-06-06 2025-12-18 Molecular Partners Ag Recombinant cd2 binding proteins and their use
WO2024251695A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd47 binding proteins and their use
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
AU2024289222A1 (en) 2023-07-05 2026-01-15 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
CA2289691C (en) 1997-04-23 2008-01-15 Andreas Pluckthun Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
DK1332209T3 (da) 2000-09-08 2010-03-29 Univ Zuerich Samlinger af repeatproteiner indeholdende repeatmoduler
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2466716T3 (es) 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1732613A2 (en) 2004-04-06 2006-12-20 Affibody AB Use of serum albumin binding peptides conjugates for the preparation of a medicament
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
RU2412249C2 (ru) 2005-07-08 2011-02-20 Юниверсити Оф Цюрих Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101528767A (zh) 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
ES2422007T3 (es) 2007-06-21 2013-09-06 Univ Muenchen Tech Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
US20110262964A1 (en) * 2008-03-19 2011-10-27 Hugues Bedouelle Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
US8901076B2 (en) * 2008-11-03 2014-12-02 Molecular Partner AG Binding proteins inhibiting the VEGF-A receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
WO2012060748A1 (en) * 2010-11-03 2012-05-10 Telefonaktiebolaget Lm Eriksson (Publ) A radio base station and a method therein
CA2818969C (en) 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
AU2012249359A1 (en) 2011-04-29 2013-11-14 Janssen Biotech, Inc. IL4/IL13 binding repeat proteins and uses
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3277711B9 (en) * 2015-04-02 2023-08-16 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048216A (ja) * 2010-11-26 2017-03-09 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血清アルブミンに結合する設計リピートタンパク質

Also Published As

Publication number Publication date
AU2011333665B2 (en) 2016-11-03
KR20140002657A (ko) 2014-01-08
BR112013012786B1 (pt) 2022-02-08
RU2013128895A (ru) 2015-01-10
KR101782790B1 (ko) 2017-09-28
BR122020011428B1 (pt) 2023-05-16
CN103459415A (zh) 2013-12-18
JP2014501509A (ja) 2014-01-23
AU2011333666A1 (en) 2013-06-06
EP3514169A1 (en) 2019-07-24
ES2758352T3 (es) 2020-05-05
DK2643349T3 (da) 2019-11-25
RU2013128896A (ru) 2015-01-10
US9221892B2 (en) 2015-12-29
US20130296221A1 (en) 2013-11-07
US20160075767A1 (en) 2016-03-17
PL2643349T3 (pl) 2020-03-31
US20130244940A1 (en) 2013-09-19
RU2636552C2 (ru) 2017-11-23
CN103403024B (zh) 2017-08-11
CN103459415B (zh) 2021-04-09
CA2818969C (en) 2020-04-14
US9775912B2 (en) 2017-10-03
ES2981441T3 (es) 2024-10-08
WO2012069655A3 (en) 2012-07-19
JP2014501510A (ja) 2014-01-23
US9284361B2 (en) 2016-03-15
AU2011333665A1 (en) 2013-06-06
US9717802B2 (en) 2017-08-01
EP2643348A2 (en) 2013-10-02
EP2643349B1 (en) 2019-09-04
EP2643349A1 (en) 2013-10-02
RU2625882C2 (ru) 2017-07-20
CN103403024A (zh) 2013-11-20
US10322190B2 (en) 2019-06-18
CA2818990C (en) 2021-06-15
WO2012069655A2 (en) 2012-05-31
KR101838037B1 (ko) 2018-03-13
JP6173216B2 (ja) 2017-08-02
KR20170046808A (ko) 2017-05-02
CA2818990A1 (en) 2012-05-31
AU2011333666B2 (en) 2017-02-02
CA2818969A1 (en) 2012-05-31
BR112013012786A2 (pt) 2016-09-13
WO2012069654A1 (en) 2012-05-31
KR20140032356A (ko) 2014-03-14
US20160250341A1 (en) 2016-09-01
JP2017048216A (ja) 2017-03-09
BR112013013043A2 (pt) 2016-09-13
US20170313748A1 (en) 2017-11-02
EP3514169B1 (en) 2024-03-06
CN113278077A (zh) 2021-08-20
EP2643348B1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
JP6105479B2 (ja) 血清アルブミンに結合する設計リピートタンパク質
CN104508129A (zh) 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白
JP2022535106A (ja) 改善された安定性を有する設計されたアンキリン反復ドメイン
HK40059771A (en) Designed repeat proteins binding to serum albumin
HK40012160A (en) Designed repeat proteins binding to serum albumin
HK40012160B (en) Designed repeat proteins binding to serum albumin
HK1189386B (zh) 设计的与血清白蛋白结合的重复蛋白
CN115175691A (zh) 结合血清白蛋白的纤连蛋白iii型结构域及其应用
HK1189386A (en) Designed repeat proteins binding to serum albumin
HK1189387B (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
HK1189387A (en) Improved n-terminal capping modules for designed ankyrin repeat proteins

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140924

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161028

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170302

R150 Certificate of patent or registration of utility model

Ref document number: 6105479

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250